AIG
GNMX

American International Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

American International Group’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,106
Closed -$28K – 3156
2017
Q1 		$28K Buy
15,106
+1,096
+8% +$4.96K ﹤0.01% 2933
2016
Q4 		$73K Sell
14,010
-37
-0.3% -$195 ﹤0.01% 2753
2016
Q3 		$78.2K Buy
14,047
+21
+0.1% +$120 ﹤0.01% 2744
2016
Q2 		$77.8K Buy
14,026
+4,070
+41% +$21.4K ﹤0.01% 2777
2016
Q1 		$43K Buy
9,956
+100
+1% +$412 ﹤0.01% 3954
2015
Q4 		$59K Sell
9,856
-17
-0.2% -$115 ﹤0.01% 3828
2015
Q3 		$77K Buy
9,873
+11
+0.1% +$85 ﹤0.01% 3688
2015
Q2 		$60.5K Buy
+9,862
New +$76.4K ﹤0.01% 3968

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

American International Group's GNMX Position: Q2 2017 in Review

American International Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 15,106 shares — an estimated $28K sold.

American International Group first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $78.2K in Q3 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • American International Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • American International Group sold 15,106 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $28K.
  • American International Group first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
  • American International Group's Aevi Genomic Medicine Inc position peaked at $78.2K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on American International Group's 13F filing for Q2 2017, filed 11 Aug 2017.